CRISPR Therapeutics (CRSP) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

GrantCollaboration Revenue
0250K500K750K1M1M2M2M2MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
0250K500K750K1M1M2M2M2MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Operating Expenses

Research And Development ExpensesGeneral And Administrative ExpensesOther Expenses
025M50M75M100M125M150M175M200MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
-200M-175M-150M-125M-100M-75M-50M-25M1Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

Revenue Variation (%)

Revenue Variation
-200-165-130-95-60-25104580Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
062125188250312375438500Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
-200-164-128-91-55-19185490Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
062125188250312375438500Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
-20-17-15-12-10-7-4-21Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Per Share Metrics

Operating IncomeTotal Other Income Expenses NetNet Income
05M10M15M20M25M30M35M40MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
💰 Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Cash Flow to Debt Ratio

Cash At End Of Period
062M125M188M250M312M375M438M500MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
🏦 Balance Sheet
📈 Key Metrics